Onartuzumab Biosimilar - Research Grade

Human

MET

>1mg/ml

Human Fab - G1 - kappa

CHO Cells

Emibetuzumab Biosimilar - Research Grade (ICH5148), Telisotuzumab Biosimilar - Research Grade (ICH5315), Davutamig Biosimilar - Research Grade (ICH5468)

https://www.imgt.org/mAb-DB/

ICH3002

P08581

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of onartuzumab, an antibody directed against human MET (hepatocyte growth factor receptor, c-Met). Onartuzumab is distinctive as a monovalent, one-armed antibody engineered to block ligand-driven receptor dimerisation without triggering agonist activity; the "Human Fab - G1 - kappa" descriptor reflects this monovalent, single antigen-binding format. Supplied for research use only, it is intended as a target-binding reagent for laboratory work, not for human or veterinary use. Typical applications include use as a positive control or benchmark in MET binding and neutralisation assays, receptor-signalling studies, epitope and competition work, ADCC or antibody-drug-conjugate development pipelines, and preclinical in-vitro and in-vivo model systems. Material is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), in an unconjugated format suitable for downstream labelling, and available in bulk milligram-to-gram quantities to support screening, assay standardisation, and scale-up. It is a research analog built around the MET target, not the clinical drug product. MET (UniProt P08581), also called c-Met or hepatocyte growth factor receptor, is a single-pass transmembrane receptor tyrosine kinase. Its only known ligand is hepatocyte growth factor/scatter factor (HGF/SF). Ligand binding promotes receptor dimerisation and trans-autophosphorylation of the intracellular kinase domain, creating docking sites that recruit adaptors such as GRB2 and GAB1 and activate the RAS-MAPK, PI3K-AKT, and STAT3 pathways. This signalling drives cell proliferation, survival, motility, scattering, invasion, and branching morphogenesis, and is essential in embryonic development, liver regeneration, and wound healing. Aberrant MET activation, through gene amplification, activating mutations, protein overexpression, or autocrine/paracrine HGF loops, is implicated in tumour growth, invasion, metastasis, and resistance to other targeted therapies, making MET a widely studied oncology target.

MetMAb, OA-5D5, OA5D5, PRO 143966;met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2

Detects MET

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.